Unknown

Dataset Information

Association of Renin-Angiotensin Inhibitor Treatment With Mortality and Heart Failure Readmission in Patients With Transcatheter Aortic Valve Replacement.


ABSTRACT:

Importance

Data are lacking on the effect of a renin-angiotensin system (RAS) inhibitor prescribed after transcatheter aortic valve replacement (TAVR). Treatment with a RAS inhibitor may reverse left ventricular remodeling and improve function.

Objective

To investigate the association of prescription of a RAS inhibitor and outcomes after TAVR.

Design, setting, and participants

Retrospective cohort study of TAVR procedures performed in the United States (using the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapies Registry) between July 2014 and January 2016 that were linked to Medicare claims data (final date of follow-up: March 31, 2017). To account for differences in demographics, echocardiographic findings, and in-hospital com

SUBMITTER: Inohara T 

PROVIDER: S-EPMC6583475 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature